Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InspireMD (NSPR) EBITDA (2016 - 2025)

Historic EBITDA for InspireMD (NSPR) over the last 16 years, with Q3 2025 value amounting to -$13.1 million.

  • InspireMD's EBITDA fell 5423.07% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.9 million, marking a year-over-year decrease of 5661.57%. This contributed to the annual value of -$33.5 million for FY2024, which is 5845.91% down from last year.
  • InspireMD's EBITDA amounted to -$13.1 million in Q3 2025, which was down 5423.07% from -$13.0 million recorded in Q2 2025.
  • InspireMD's EBITDA's 5-year high stood at -$3.3 million during Q1 2021, with a 5-year trough of -$13.1 million in Q3 2025.
  • In the last 5 years, InspireMD's EBITDA had a median value of -$5.3 million in 2023 and averaged -$6.6 million.
  • As far as peak fluctuations go, InspireMD's EBITDA crashed by 8364.46% in 2021, and later surged by 234.06% in 2023.
  • InspireMD's EBITDA (Quarter) stood at -$3.9 million in 2021, then dropped by 25.57% to -$4.9 million in 2022, then fell by 17.67% to -$5.8 million in 2023, then plummeted by 61.28% to -$9.4 million in 2024, then tumbled by 39.33% to -$13.1 million in 2025.
  • Its EBITDA was -$13.1 million in Q3 2025, compared to -$13.0 million in Q2 2025 and -$11.5 million in Q1 2025.